摘要
目的 :研究CA12 5及其半衰期监测进展期卵巢癌疗效及预后的应用价值。方法 :采用化学发光法测定 45例Ⅲ、Ⅳ期原发卵巢癌患者血浆CA12 5水平并计算CA12 5半衰期。结果 :45例患者治疗前血浆CA12 5水平均高于正常 ;采用单因素生存率时序检验 (Logranktest)分析表明 ,第 3次化疗后CA12 5水平、CA12 5半衰期及手术后残留灶大小、FIGO分期对预后有影响 (P值分别为 0 0 0 10、0 0 0 0 0、0 0 0 0 2、0 0 3 85 ) ;运用Cox风险回归模型进行多因素分析表明 :CA12 5半衰期对进展期卵巢癌患者有独立的预后价值 (χ2 =6 2 73 4,P =0 0 12 3 )。结论 :化疗早期CA12 5水平及其半衰期对进展期卵巢癌患者的预后评定有价值 ,检测该指标可及时发现耐药或复发 ,可及时给予相应的治疗措施。
Objective:To evaluate the value of serum CA125 and its half-life as a marker in monitoring the response to treatment and prognosis of advanced ovarian cancer.Method:Automated chemiluminescence system was used to detect the levels of serum CA125 in 45 stages Ⅲ and Ⅳ primary ovarian cancer patients.Result:①Pretreatment serum CA125 levels in 45 advanced ovarian cancer patients were significantly higher-than 35u/ml.②Univariate analysis shows statistical significance for survival for the following investigated variables:serum CA125 levels after the third cycle of chemotherapy?CA125 half-life and residual disease?FIGO stage(P=0 0010?0 0000?0 0002?0 0385,respectively).③In a survival analysis using the Cox proportional CA125 half-life calculation showed an independent prognostic significant(χ 2=6 2734,P=0 0123).Conclusion:This suggested CA125 levels of the early period of chemotherapy and serum half-life had earlier and more reliable value.If used clinically,it may help to find drug resitance or recurrence in time so as to take corresponding treating measures early.
出处
《江苏临床医学杂志》
2002年第4期340-342,共3页
Journal of Jiangsu Clinical Medicine